[somatropin (rDNA origin) for injection]
Zorbtive®, a recombinant human growth hormone, is a significant treatment advance and was approved in 2003 with orphan drug marketing exclusivity until 2010. The active ingredient in Zorbtive® is growth hormone. Growth hormone has been shown in human clinical studies to increase the absorption of water, electrolytes, and nutrients. As a result, patients prescribed Zorbtive® may be able to reduce dependence on parenteral nutrition for the body's required fluids and nutrients.
Important Safety Information
Growth hormone therapy should not be initiated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure. Zorbtive® [somatropin (rDNA origin) for injection] is indicated for the treatment of Short Bowel Syndrome in patients receiving specialized nutritional support. Zorbtive® therapy should be used in conjunction with optimal management of Short Bowel Syndrome.